Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Navidea price target raised to $6 from $4 at H.C. Wainwright » 12:21
05/22/20
05/22
12:21
05/22/20
12:21
NAVB

Navidea

$2.48 /

+1.16 (+87.88%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Vernon Bernardino raised the firm's price target on Navidea to $6 from $4 and keeps a Buy rating on the shares after the company announced "positive" preliminary results from its second interim analysis of its ongoing NAV3-31 Phase 2b study with tilmanocept. Bernardino believes the interim data analysis further corroborates the company's hypotheses that tilmanocept imaging can provide "robust, quantitative" imaging in healthy controls and in patients with active rheumatoid arthritis. The analyst added that he is positive on the results, as they boost the technology's chances of success for approval as a new imaging tool in RA.

ShowHide Related Items >><<
NAVB Navidea
$2.48 /

+1.16 (+87.88%)

NAVB Navidea
$2.48 /

+1.16 (+87.88%)

11/22/19 H.C. Wainwright
Navidea initiated with a Buy at H.C. Wainwright
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
NAVB Navidea
$2.48 /

+1.16 (+87.88%)

Thursday
On The Fly
Fly Intel: After-Hours Movers » 19:01
05/21/20
05/21
19:01
05/21/20
19:01
PANW

Palo Alto Networks

$229.36 /

-4.89 (-2.09%)

, RAMP

LiveRamp

$38.70 /

-0.16 (-0.41%)

, CRMT

America's Car-Mart

$73.77 /

+2.825 (+3.98%)

, ELF

e.l.f. Beauty

$14.56 /

+0.34 (+2.39%)

, A

Agilent

$80.84 /

-0.83 (-1.02%)

, SPLK

Splunk

$163.27 /

+0.11 (+0.07%)

, DECK

Deckers Brands

$167.93 /

+5.83 (+3.60%)

, PRSP

Perspecta

$22.93 /

-0.4 (-1.71%)

, PLUS

ePlus

$76.14 /

+4.14 (+5.75%)

, NAVB

Navidea

$1.32 /

+0.06 (+4.76%)

, USFD

US Foods

$18.56 /

-0.24 (-1.28%)

, NYMT

New York Mortgage

$2.04 /

+0.105 (+5.43%)

, AGYS

Agilysys

$20.11 /

+0.79 (+4.09%)

, HPE

HP Enterprise

$10.35 /

+0.07 (+0.68%)

, LGF.A

Lionsgate

$8.61 /

+0.13 (+1.53%)

, ROST

Ross Stores

$97.01 /

+6.1 (+6.71%)

, INTU

Intuit

$290.30 /

-0.4 (-0.14%)

, CHUY

Chuy's

$16.13 /

+0.09 (+0.56%)

, NVDA

Nvidia

$351.01 /

-7.78 (-2.17%)

, SNDX

Syndax

$20.51 /

+0.34 (+1.69%)

, GERN

Geron

$1.95 /

+0.06 (+3.17%)

, CFRX

ContraFect

$5.38 /

-0.22 (-3.93%)

, DSS

Document Security

$8.50 /

+0.22 (+2.66%)

, H

Hyatt

$53.45 /

-0.49 (-0.91%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
USFD US Foods
$18.56 /

-0.24 (-1.28%)

SPLK Splunk
$163.27 /

+0.11 (+0.07%)

SNDX Syndax
$20.51 /

+0.34 (+1.69%)

ROST Ross Stores
$97.01 /

+6.1 (+6.71%)

RAMP LiveRamp
$38.70 /

-0.16 (-0.41%)

PRSP Perspecta
$22.93 /

-0.4 (-1.71%)

PLUS ePlus
$76.14 /

+4.14 (+5.75%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

NYMT New York Mortgage
$2.04 /

+0.105 (+5.43%)

NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

NAVB Navidea
$1.32 /

+0.06 (+4.76%)

LGF.A Lionsgate
$8.61 /

+0.13 (+1.53%)

INTU Intuit
$290.30 /

-0.4 (-0.14%)

HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

H Hyatt
$53.45 /

-0.49 (-0.91%)

GERN Geron
$1.95 /

+0.06 (+3.17%)

ELF e.l.f. Beauty
$14.56 /

+0.34 (+2.39%)

DSS Document Security
$8.50 /

+0.22 (+2.66%)

DECK Deckers Brands
$167.93 /

+5.83 (+3.60%)

CRMT America's Car-Mart
$73.77 /

+2.825 (+3.98%)

CHUY Chuy's
$16.13 /

+0.09 (+0.56%)

CFRX ContraFect
$5.38 /

-0.22 (-3.93%)

AGYS Agilysys
$20.11 /

+0.79 (+4.09%)

A Agilent
$80.84 /

-0.83 (-1.02%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

05/20/20 Wells Fargo
Palo Alto Networks price target raised to $250 from $225 at Wells Fargo
05/20/20 Monness Crespi
Palo Alto Networks price target raised to $255 from $210 at Monness Crespi
05/19/20 Dougherty
Dougherty sees Palo Alto set up for rebound, upgrades to Buy
05/19/20 Dougherty
Palo Alto Networks upgraded to Buy from Neutral at Dougherty
RAMP LiveRamp
$38.70 /

-0.16 (-0.41%)

04/27/20 Needham
LiveRamp price target lowered to $57 from $70 at Needham
04/21/20 Berenberg
LiveRamp initiated with a Buy at Berenberg
03/13/20 Stephens
LiveRamp weakness creates 'real opportunity,' says Stephens
01/26/20 First Analysis
First Analysis sees continued top-line momentum in 2020 for LiveRamp
CRMT America's Car-Mart
$73.77 /

+2.825 (+3.98%)

03/27/20 Stephens
America's Car-Mart upgraded to Overweight from Equal Weight at Stephens
02/13/20 Janney Montgomery Scott
America's Car-Mart downgraded to Neutral from Buy at Janney Montgomery Scott
ELF e.l.f. Beauty
$14.56 /

+0.34 (+2.39%)

04/08/20 Piper Sandler
Piper lays out winners and losers in survey of 5,200 teens
03/18/20 DA Davidson
e.l.f. Beauty price target lowered to $12 from $24.50 at DA Davidson
02/06/20 Piper Sandler
e.l.f. Beauty price target raised to $23 from $19 at Piper Sandler
02/04/20
Fly Intel: Top five analyst upgrades
A Agilent
$80.84 /

-0.83 (-1.02%)

03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/19/20 Piper Sandler
Agilent price target raised to $96 from $86 at Piper Sandler
SPLK Splunk
$163.27 /

+0.11 (+0.07%)

05/14/20 Cleveland Research
Splunk estimates at risk amid enterprise weakness, says Cleveland Research
04/27/20 Needham
Splunk price target lowered to $168 from $181 at Needham
04/24/20 Cowen
Splunk downgraded to Market Perform at Cowen
04/24/20 Cowen
Splunk downgraded to Market Perform from Outperform at Cowen
DECK Deckers Brands
$167.93 /

+5.83 (+3.60%)

05/18/20 Wedbush
Deckers Brands price target raised to $155 from $145 at Wedbush
05/15/20 Pivotal Research
Deckers Brands price target lowered to $165 from $217 at Pivotal Research
05/14/20 Wells Fargo
Wells Fargo downgrades Steven Madden to Underweight on brand weakness
04/28/20 BTIG
Deckers Brands initiated with a Buy at BTIG
PRSP Perspecta
$22.93 /

-0.4 (-1.71%)

04/02/20 Wells Fargo
Perspecta price target lowered to $18.50 from $26 at Wells Fargo
03/30/20 William Blair
Perspecta initiated with a Market Perform at William Blair
03/25/20 Wells Fargo
Good news for government contractors in COVID -19 bill, says Wells Fargo
02/25/20 Morgan Stanley
Morgan Stanley upgrades Perspecta to Equal Weight on overhang removal
PLUS ePlus
$76.14 /

+4.14 (+5.75%)

02/11/20 Berenberg
ePlus upgraded to Buy from Hold at Berenberg
02/06/20 Sidoti
ePlus upgraded to Buy after earnings at Sidoti
02/06/20 Sidoti
ePlus upgraded to Buy from Neutral at Sidoti
11/14/19 Sidoti
ePlus downgraded to Neutral from Buy at Sidoti
NAVB Navidea
$1.32 /

+0.06 (+4.76%)

11/22/19 H.C. Wainwright
Navidea initiated with a Buy at H.C. Wainwright
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
USFD US Foods
$18.56 /

-0.24 (-1.28%)

05/18/20 Guggenheim
US Foods price target lowered to $30 from $50 at Guggenheim
04/27/20 Credit Suisse
US Foods price target lowered to $27 from $47 at Credit Suisse
04/23/20 BMO Capital
US Foods downgraded to Market Perform from Outperform at BMO Capital
04/06/20 JPMorgan
US Foods price target lowered to $24 from $45 at JPMorgan
NYMT New York Mortgage
$2.04 /

+0.105 (+5.43%)

04/24/20 Credit Suisse
New York Mortgage upgraded to Neutral from Underperform at Credit Suisse
04/24/20 Credit Suisse
New York Mortgage upgraded to Neutral from Underperform at Credit Suisse
03/25/20 Maxim
AGNC Investment, New York Mortgage Trust cut to Hold at Maxim
03/25/20 Maxim
New York Mortgage downgraded to Hold from Buy at Maxim
AGYS Agilysys
$20.11 /

+0.79 (+4.09%)

04/16/20 BTIG
Agilysys initiated with a Neutral at BTIG
03/16/20 Craig-Hallum
Agilysys price target lowered to $27 from $40 at Craig-Hallum
01/29/20 Craig-Hallum
Agilysys price target raised to $40 from $32 at Craig-Hallum
12/03/19 Craig-Hallum
Agilysys initiated with a Buy at Craig-Hallum
HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

05/19/20 Barclays
Barclays lowers estimates in IT hardware after April survey
04/27/20 Loop Capital
Xerox, Park City, NetApp, HP Enterprise cut to Hold from Buy at Loop Capital
04/27/20 Loop Capital
HP Enterprise downgraded to Hold from Buy at Loop Capital
04/22/20
Fly Intel: Top five analyst initiations
LGF.A Lionsgate
$8.61 /

+0.13 (+1.53%)

04/27/20 RBC Capital
Lionsgate initiated with a Sector Perform at RBC Capital
04/22/20 Deutsche Bank
Lionsgate price target lowered to $10 from $22 at Deutsche Bank
04/21/20 JPMorgan
Lionsgate price target lowered to $11 from $14 at JPMorgan
03/23/20
Lionsgate participates in a conference call with SunTrust
ROST Ross Stores
$97.01 /

+6.1 (+6.71%)

05/19/20 Jefferies
TJX to benefit from 'biggest liquidation sale in history,' says Jefferies
05/11/20 Nomura Instinet
Ross Stores price target raised to $100 from $80 at Nomura Instinet
04/28/20 DA Davidson
Ross Stores upgraded to Buy from Neutral at DA Davidson
04/28/20 DA Davidson
Ross Stores upgraded to Buy from Neutral at DA Davidson
INTU Intuit
$290.30 /

-0.4 (-0.14%)

05/19/20 KeyBanc
Intuit price target raised to $315 from $285 at KeyBanc
05/05/20 KeyBanc
Intuit price target raised to $285 from $275 at KeyBanc
04/17/20 RBC Capital
Intuit lowered to $280 from $345 at RBC Capital
04/13/20 Jefferies
Jefferies continues to like Intuit after approval for small business lending
CHUY Chuy's
$16.13 /

+0.09 (+0.56%)

04/23/20 BMO Capital
Chuy's upgraded to Market Perform from Underperform at BMO Capital
04/20/20 Raymond James
Chuy's price target raised to $17 from $14 at Raymond James
04/08/20 Wedbush
Chuy's price target lowered to $17 from $26 at Wedbush
04/02/20 Raymond James
Chuy's upgraded to Outperform from Market Perform at Raymond James
NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

05/21/20 Credit Suisse
Nvidia reinstated with an Outperform at Credit Suisse
05/19/20 RBC Capital
Nvidia price target raised to $385 from $350 at RBC Capital
05/19/20 Susquehanna
Nvidia price target raised to $410 from $355 at Susquehanna
05/18/20
Fly Intel: Top five analyst upgrades
SNDX Syndax
$20.51 /

+0.34 (+1.69%)

05/18/20 Citi
Syndax downgraded to Neutral from Buy at Citi
05/11/20 H.C. Wainwright
Syndax price target raised to $25 from $19 at H.C. Wainwright
05/08/20 Nomura Instinet
Syndax price target raised to $31 from $16 at Nomura Instinet
05/04/20 Baird
Syndax risk/reward solid following positive clinical data, says Baird
GERN Geron
$1.95 /

+0.06 (+3.17%)

11/19/19 B. Riley FBR
B. Riley FBR resumes Geron with Buy rating, $4 price target
11/19/19 B. Riley FBR
Geron resumed with a Buy at B. Riley FBR
09/03/19 H.C. Wainwright
Geron initiated with a Buy at H.C. Wainwright
08/15/19 Cantor Fitzgerald
Geron initiated with an Overweight at Cantor Fitzgerald
CFRX ContraFect
$5.38 /

-0.22 (-3.93%)

10/02/19 Piper Sandler
Piper says design differentiates ContraFect trial from other antibiotic studies
06/11/19 Maxim
ContraFect initiated with a Buy at Maxim
DSS Document Security
$8.50 /

+0.22 (+2.66%)

10/10/19 Aegis
Document Security initiated with a Buy rating at Aegis
H Hyatt
$53.45 /

-0.49 (-0.91%)

05/08/20
Fly Intel: Top five analyst downgrades
05/08/20 Deutsche Bank
Hyatt price target lowered to $54 from $86 at Deutsche Bank
05/08/20 Macquarie
Hyatt downgraded to Neutral from Outperform at Macquarie
04/22/20 BofA
Choice Hotels upgraded to Neutral from Underperform at Bofa
USFD US Foods
$18.56 /

-0.24 (-1.28%)

SPLK Splunk
$163.27 /

+0.11 (+0.07%)

SNDX Syndax
$20.51 /

+0.34 (+1.69%)

ROST Ross Stores
$97.01 /

+6.1 (+6.71%)

RAMP LiveRamp
$38.70 /

-0.16 (-0.41%)

PRSP Perspecta
$22.93 /

-0.4 (-1.71%)

PLUS ePlus
$76.14 /

+4.14 (+5.75%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

NYMT New York Mortgage
$2.04 /

+0.105 (+5.43%)

NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

LGF.A Lionsgate
$8.61 /

+0.13 (+1.53%)

INTU Intuit
$290.30 /

-0.4 (-0.14%)

HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

H Hyatt
$53.45 /

-0.49 (-0.91%)

GERN Geron
$1.95 /

+0.06 (+3.17%)

ELF e.l.f. Beauty
$14.56 /

+0.34 (+2.39%)

DSS Document Security
$8.50 /

+0.22 (+2.66%)

DECK Deckers Brands
$167.93 /

+5.83 (+3.60%)

CRMT America's Car-Mart
$73.77 /

+2.825 (+3.98%)

CHUY Chuy's
$16.13 /

+0.09 (+0.56%)

CFRX ContraFect
$5.38 /

-0.22 (-3.93%)

AGYS Agilysys
$20.11 /

+0.79 (+4.09%)

A Agilent
$80.84 /

-0.83 (-1.02%)

  • 22
    May
  • 22
    May
  • 22
    May
ROST Ross Stores
$97.01 /

+6.1 (+6.71%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

LGF.A Lionsgate
$8.61 /

+0.13 (+1.53%)

INTU Intuit
$290.30 /

-0.4 (-0.14%)

HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

H Hyatt
$53.45 /

-0.49 (-0.91%)

A Agilent
$80.84 /

-0.83 (-1.02%)

USFD US Foods
$18.56 /

-0.24 (-1.28%)

SPLK Splunk
$163.27 /

+0.11 (+0.07%)

SNDX Syndax
$20.51 /

+0.34 (+1.69%)

RAMP LiveRamp
$38.70 /

-0.16 (-0.41%)

PRSP Perspecta
$22.93 /

-0.4 (-1.71%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

NYMT New York Mortgage
$2.04 /

+0.105 (+5.43%)

NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

LGF.A Lionsgate
$8.61 /

+0.13 (+1.53%)

INTU Intuit
$290.30 /

-0.4 (-0.14%)

HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

H Hyatt
$53.45 /

-0.49 (-0.91%)

ELF e.l.f. Beauty
$14.56 /

+0.34 (+2.39%)

DECK Deckers Brands
$167.93 /

+5.83 (+3.60%)

CHUY Chuy's
$16.13 /

+0.09 (+0.56%)

A Agilent
$80.84 /

-0.83 (-1.02%)

SPLK Splunk
$163.27 /

+0.11 (+0.07%)

ROST Ross Stores
$97.01 /

+6.1 (+6.71%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

NYMT New York Mortgage
$2.04 /

+0.105 (+5.43%)

NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

INTU Intuit
$290.30 /

-0.4 (-0.14%)

HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

H Hyatt
$53.45 /

-0.49 (-0.91%)

A Agilent
$80.84 /

-0.83 (-1.02%)

Hot Stocks
Navidea surges nearly 30% after 'positive' arthritis study results » 16:51
05/21/20
05/21
16:51
05/21/20
16:51
NAVB

Navidea

$1.32 /

+0.06 (+4.76%)

Shares of Navidea…

Shares of Navidea Biopharmaceuticals (NAVB) jumped 29.9% after the company announced "positive" results from the company's second interim analysis of its ongoing NAV3-31 Phase 2B study. Navidea said that analysis shows that these interim data further corroborate its hypotheses that Tc99m tilmanocept imaging can provide robust, quantitative imaging in healthy controls and in patients with active rheumatoid arthritis, and that this imaging can provide an early indicator of treatment efficacy in patients with active RA. Michael Rosol, Chief Medical Officer for Navidea, said, "We are encouraged by these interim results, which are in line with our hypotheses, support the continuation of the current Phase 2B study, and will be fundamental to speaking with the FDA about moving forward into the Phase 3 trial later this year." Dr. Rosol continued, "We are excited that we are on track to possibly providing rheumatologists and those suffering with RA a noninvasive, quantifiable, early indicator of whether or not an anti-TNF alpha treatment is working. This could bring enormous benefit to these patients by assisting physicians in putting them on the right course of treatment earlier than would otherwise be possible today."

ShowHide Related Items >><<
NAVB Navidea
$1.32 /

+0.06 (+4.76%)

NAVB Navidea
$1.32 /

+0.06 (+4.76%)

11/22/19 H.C. Wainwright
Navidea initiated with a Buy at H.C. Wainwright
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
Hot Stocks
Navidea reports 'positive' preliminary results from ongoing Phase 2B RA study » 16:31
05/21/20
05/21
16:31
05/21/20
16:31
NAVB

Navidea

$1.32 /

+0.06 (+4.76%)

Navidea…

Navidea Biopharmaceuticals announced "positive" preliminary results from the Company's second interim analysis of its ongoing NAV3-31 Phase 2B study. Analysis demonstrates that these interim data further corroborate Navidea's hypotheses that Tc99m tilmanocept imaging can provide robust, quantitative imaging in healthy controls and in patients with active rheumatoid arthritis, and that this imaging can provide an early indicator of treatment efficacy in patients with active RA. A total of 15 subjects with active moderate-to-severe RA were included in this interim analysis, each of which was set to begin a new or first-time treatment regimen with an anti-TNF alpha therapy. Whole body and hand/wrist planar gamma camera images were obtained at baseline prior to initiation of new treatment, again at 5 weeks post therapy initiation, and then again at 12 weeks on 8 of the 15 subjects. The remaining 7 subjects had received baseline and 5-week scans only at the time of this analysis. A panel of established clinical assessments was performed at each time point as well, in order to compare imaging results with clinical standards over the 12-week time course. Results of the preliminary analysis demonstrate: Tc99m tilmanocept imaging from baseline to week 5 was predictive of clinical outcome at 12 weeks in 7 out of 8 subjects with 12-week clinical assessment available at the time of the interim analysis. The one subject who did not demonstrate concordance of signal quantification and clinical assessment had undergone a change in treatment regime while enrolled in the trial that may have impacted the trajectory of the clinical response. Combined data from all 15 subjects in Arm 3 suggest a wide dynamic range of more than one order of magnitude (greater than10-fold) for calculated global Tc99m tilmanocept uptake values in joints with RA-involved inflammation. In the subjects with 12-week follow up data available, global Tc99m tilmanocept signals declined by an average of 58% from baseline to week 5 in those who responded significantly to anti-TNF alpha treatment by week 12. In those subjects who did not have a significant clinical response to anti-TNF alpha treatment by week 12, Tc99m tilmanocept signals increased by an average of 79% from baseline to 5 weeks. These preliminary results indicate that marked changes in Tc99m tilmanocept global uptake values by week 5 are in agreement with clinical efficacy evaluations made at week 12 of treatment. The wide dynamic range of global Tc99m tilmanocept signal readout combined with the low variability of imaging signal quantification established in Arms 1 and 2 of this trial are supportive of the idea that clinically meaningful changes in signal localization can be detected. These interim data are supportive of Navidea's hypotheses that Tc99m tilmanocept imaging can provide quantifiable imaging assessment of RA-involved joints that enables early prediction of clinical response as well as longitudinal monitoring of clinical status.

ShowHide Related Items >><<
NAVB Navidea
$1.32 /

+0.06 (+4.76%)

NAVB Navidea
$1.32 /

+0.06 (+4.76%)

11/22/19 H.C. Wainwright
Navidea initiated with a Buy at H.C. Wainwright
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
Over a week ago
Hot Stocks
Navidea regains commercialization, distribution rights in EU for LYMPHOSEEK » 07:36
05/11/20
05/11
07:36
05/11/20
07:36
NAVB

Navidea

$0.93 /

-0.0001 (-0.01%)

Navidea…

Navidea Biopharmaceuticals announces that the company has regained the commercialization and distribution rights in Europe for LYMPHOSEEK injection from Norgine B.V. Navidea and Norgine have decided, by mutual agreement, to end the existing license agreement between the two companies. The Agreement was originally entered in March 2015, and provided Norgine with the exclusive rights in Europe for LYMPHOSEEK. As a result of today's transaction, Navidea has regained all the rights, economics, and intellectual property of LYMPHOSEEK in Europe.

ShowHide Related Items >><<
NAVB Navidea
$0.93 /

-0.0001 (-0.01%)

11/22/19 H.C. Wainwright
Navidea initiated with a Buy at H.C. Wainwright
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
Over a month ago
Hot Stocks
Navidea issues statement, clinical trial update amid COVID-19 pandemic » 07:35
04/22/20
04/22
07:35
04/22/20
07:35
NAVB

Navidea

$0.73 /

+0.0309 (+4.45%)

Navidea announced the…

Navidea announced the following statement regarding the impact of the COVID-19 pandemic on the company's ongoing clinical development efforts: "First, we would like to express our sincerest gratitude for all of the healthcare workers and other responders on the frontlines who are working tirelessly to combat this global pandemic. This has affected us all. We wanted to share Navidea's response during this time of crisis and provide an update on our research and development activities. Navidea is on track to deliver interim data from arm 3 of the Company's Phase 2b clinical trial (NAV3-31) in the timeframe previously communicated on the March 11, 2020 quarterly update call. Navidea has enrolled sufficient patients to meet these previously communicated timelines." In regards to the company's planned meeting with the FDA, management has made no changes to its internal forecast of an FDA meeting in late Q2/early Q3. Management believes that sufficient patients have been enrolled to maintain the previous forecast. The NAV3-33 trial, pivotal Phase 3 trial for rheumatoid arthritis, remains on track for a second-half 2020 launch. This goal echoes guidance previously provided on the March 11 quarterly update call. Analysis of the data from the company's Cardiovascular Phase 2b study remains on track. Results provided to Navidea thus far have paralleled data in our earlier published article. These data are supportive of Navidea's hypothesis that Tilmanocept can provide marked signal to background in a host of cardiovascular disease applications. Navidea continues to anticipate meeting with the FDA in the coming months to discuss upcoming clinical trial designs.

ShowHide Related Items >><<
NAVB Navidea
$0.73 /

+0.0309 (+4.45%)

11/22/19 H.C. Wainwright
Navidea initiated with a Buy at H.C. Wainwright
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
Hot Stocks
Navidea signs LOI to partner with WorldCare for RA clinical imaging workflow » 07:43
03/31/20
03/31
07:43
03/31/20
07:43
NAVB

Navidea

$0.79 /

-0.0001 (-0.01%)

Navidea announced that it…

Navidea announced that it has signed a letter of intent, or LOI, to partner with WorldCare Clinical for the company's rheumatoid arthritis, or RA, diagnostic clinical imaging workflow. Per the agreement, WorldCare would serve as Navidea's central imaging service provider following FDA approval of Navidea's RA diagnostic. WorldCare Clinical is an independent contract research organization dedicated to imaging in clinical trials and brings with it over 25 years of clinical trial imaging, commercial clinical imaging and large-scale data management experience. WorldCare and Navidea will work in conjunction during the completion of Navidea's ongoing and planned RA diagnostic trials. The partnership will work to develop the commercial workflow and infrastructure to support the full-scale commercialization plan for Navidea's RA diagnostic. It is anticipated that WorldCare will be the vendor managing the imaging aspects of the upcoming Phase 2b and Phase 3 clinical trials, and will work in parallel to develop an optimized workflow in preparation for commercial launch in indications in RA. The company's audited financial statements contained a going concern explanatory paragraph in the audit opinion from its independent registered public accounting firm. This announcement is required pursuant to NYSE American Company Guide Sections 401 and 610, and does not represent any change or amendment to the company's financial statements or to its annual report on Form 10-K for FY19.

ShowHide Related Items >><<
NAVB Navidea
$0.79 /

-0.0001 (-0.01%)

11/22/19 H.C. Wainwright
Navidea initiated with a Buy at H.C. Wainwright
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
Hot Stocks
Navidea announces extension certificate for Lymphoseek patent from USPTO » 07:04
03/20/20
03/20
07:04
03/20/20
07:04
NAVB

Navidea

$0.79 /

-0.0022 (-0.28%)

, CAH

Cardinal Health

$43.61 /

-1.86 (-4.09%)

Navidea (NAVB) announced…

Navidea (NAVB) announced that the U.S. Patent and Trademark Office, or USPTO, issued a certificate to extend the duration of U.S. patent 6,409,990 for an additional five years through May 12, 2025. This certificate was based on the FDA recommendation for a five-year extension under the Hatch-Waxman Act for patent term lost in regulatory review. This patent claims and protects Lymphoseek and has been exclusively licensed with varying geographical and medical indication coverages to Cardinal Health (CAH) and Navidea. Allowance of this patent extension will permit Cardinal Health and Navidea to extend their exclusive rights to manufacture and commercialize Lymphoseek until the end of the extended patent term in 2025.

ShowHide Related Items >><<
NAVB Navidea
$0.79 /

-0.0022 (-0.28%)

11/22/19 H.C. Wainwright
Navidea initiated with a Buy at H.C. Wainwright
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
CAH Cardinal Health
$43.61 /

-1.86 (-4.09%)

03/20/20 BofA
Cardinal Health upgraded to Buy from Underperform at BofA
02/12/20 Morgan Stanley
Cardinal Health upgraded to Equal Weight from Underweight at Morgan Stanley
02/07/20 Baird
Cardinal Health upgraded to Outperform at Baird
02/07/20 Mizuho
Cardinal Health price target raised to $58 from $52 at Mizuho
Over a quarter ago
Hot Stocks
Navidea trading resumes  12:10
02/14/20
02/14
12:10
02/14/20
12:10
NAVB

Navidea

$1.17 /

+0.18 (+18.18%)

 
ShowHide Related Items >><<
NAVB Navidea
$1.17 /

+0.18 (+18.18%)

11/22/19 H.C. Wainwright
Navidea initiated with a Buy at H.C. Wainwright
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
Hot Stocks
Navidea regains compliance with NYSE American listing standards » 12:05
02/14/20
02/14
12:05
02/14/20
12:05
NAVB

Navidea

$1.17 /

+0.18 (+18.18%)

Navidea…

Navidea Biopharmaceuticals announced that following its recently announced funding transactions, the company is back in compliance with the NYSE American's continued listing standards. Following the funding transactions, the company now has stockholders' equity of $6.0M, and therefore has regained compliance with the NYSE American's continued listing standards.

ShowHide Related Items >><<
NAVB Navidea
$1.17 /

+0.18 (+18.18%)

11/22/19 H.C. Wainwright
Navidea initiated with a Buy at H.C. Wainwright
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
07/11/19 Maxim
Navidea initiated with a Buy at Maxim

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.